Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects
British Journal of Pharmacology2016Vol. 173(10), pp. 1580–1588
Citations Over TimeTop 10% of 2016 papers
Malcolm Boyce, Steve Warrington, B Cortezi, Stefan Zöllner, S Vauléon, Dorine W. Swinkels, Luciana Summo, Frank Schwoebel, Kai Riecke
Abstract
Lexaptepid pegol inhibited hepcidin and dose-dependently raised serum iron and transferrin saturation. The compound is being further developed to treat anaemia of chronic disease.
Related Papers
- → Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease(2019)74 cited
- → Erythroferrone, the new iron regulator: evaluation of its levels in Egyptian patients with beta thalassemia(2019)18 cited
- → Hepcidin resistance in dysmetabolic iron overload(2016)46 cited
- → Serum Hepcidin in Haemodialysis Patients: Associations with Iron Status and Microinflammation(2011)23 cited
- → Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients(2017)9 cited